安罗替尼联合替赛珠单抗治疗伴有种系 BRCA2 基因突变的复发性转移性胰腺导管腺癌：病例报告

{"title":"安罗替尼联合替赛珠单抗治疗伴有种系 BRCA2 基因突变的复发性转移性胰腺导管腺癌：病例报告","authors":"Sujuan Peng, Hongxiang Huang, Xie Zhu, Jinhong Chen, Xinjing Ding, Fen Wang, Li Chen, Zhihui Lu","doi":"10.3892/etm.2024.12466","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":508388,"journal":{"name":"Experimental and Therapeutic Medicine","volume":" 444","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report\",\"authors\":\"Sujuan Peng, Hongxiang Huang, Xie Zhu, Jinhong Chen, Xinjing Ding, Fen Wang, Li Chen, Zhihui Lu\",\"doi\":\"10.3892/etm.2024.12466\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":508388,\"journal\":{\"name\":\"Experimental and Therapeutic Medicine\",\"volume\":\" 444\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and Therapeutic Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3892/etm.2024.12466\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and Therapeutic Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/etm.2024.12466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}